Clinical trial

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01464905

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2011-10-01

PhasePHASE3

Study timeline

Study start (unknown)2011-10-01Date precision: month

Registry last updated2013-09-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Remitting Multiple Sclerosisunresolved

Interventions

NU100BIOLOGICAL

PlaceboBIOLOGICAL

rhIFN beta-1bBIOLOGICAL

Sponsors & collaborators

Nuron Biotech Inc.lead sponsor

Mapped research locations

BarcelonaSpain1 MoscowRussia1 WarsawPoland1 BudapestHungary1 SofiaBulgaria1 BelgradeSerbia1 RomeItaly1 ZagrebCroatia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01464905 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.